Your browser doesn't support javascript.
loading
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Earl, Helena M; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes-Davies, Luke; Harnett, Adrian N; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen B; Wilcox, Maggie; Plummer, Chris; Mansi, Janine; Gounaris, Ioannis; Mahler-Araujo, Betania; Provenzano, Elena; Chhabra, Anita; Abraham, Jean E; Caldas, Carlos; Hall, Peter S; McCabe, Christopher; Hulme, Claire; Miles, David; Wardley, Andrew M; Cameron, David A; Dunn, Janet A.
Affiliation
  • Earl HM; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge Breast Cancer Research Unit, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK; National Institute for Health Research Cambridge Biomedical Research Centre, Ca
  • Hiller L; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
  • Vallier AL; Cambridge Clinical Trials Unit-Cancer Theme, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK.
  • Loi S; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
  • McAdam K; Department of Oncology, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK; Department of Oncology, North West Anglia NHS Foundation Trust, Peterborough City Hospital, Peterborough, UK.
  • Hughes-Davies L; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Department of Oncology, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK.
  • Harnett AN; Department of Oncology, James Paget University Hospital, Norfolk, UK; Department of Oncology, Norfolk & Norwich University Hospital, Norwich, UK.
  • Ah-See ML; Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK.
  • Simcock R; Sussex Cancer Centre, Brighton and Sussex University Hospitals NHS, Brighton, UK.
  • Rea D; Cancer Research UK Clinical Trials Unit and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Raj S; Department of Oncology, Southampton University Hospital NHS Foundation Trust, Southampton, UK.
  • Woodings P; Department of Oncology, Royal Derby Hospital, Derby, UK.
  • Harries M; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Howe D; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
  • Raynes K; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
  • Higgins HB; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
  • Wilcox M; Independent Cancer Patients Voice, London, UK.
  • Plummer C; Department of Cardiology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Freeman Hospital, Newcastle upon Tyne, UK.
  • Mansi J; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Gounaris I; Oncology Global Drug Development, Novartis, Basel, Switzerland.
  • Mahler-Araujo B; Metabolic Research Laboratories, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Department of Histopathology, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK.
  • Provenzano E; Department of Histopathology, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK; National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK.
  • Chhabra A; Pharmacy, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK.
  • Abraham JE; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge Breast Cancer Research Unit, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK; National Institute for Health Research Cambridge Biomedical Research Centre, Ca
  • Caldas C; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge Breast Cancer Research Unit, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK; National Institute for Health Research Cambridge Biomedical Research Centre, Ca
  • Hall PS; Cancer Edinburgh Research Centre, The Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK.
  • McCabe C; Institute of Health Economics, Edmonton, Canada.
  • Hulme C; Academic Unit of Health Economics, University of Leeds, Leeds, UK; Health Economics Group, Institute of Health Research, University of Exeter Medical School, Exeter, UK.
  • Miles D; Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK.
  • Wardley AM; Research & Development, The NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, ManchesterAcademic Health Science Centre, University of Manchester, Manchester, UK.
  • Cameron DA; Cancer Edinburgh Research Centre, The Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK.
  • Dunn JA; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
Lancet ; 393(10191): 2599-2612, 2019 06 29.
Article in En | MEDLINE | ID: mdl-31178152
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Trastuzumab / Antineoplastic Agents, Immunological Type of study: Clinical_trials / Health_technology_assessment / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Lancet Year: 2019 Type: Article Affiliation country: Canada
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Trastuzumab / Antineoplastic Agents, Immunological Type of study: Clinical_trials / Health_technology_assessment / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Lancet Year: 2019 Type: Article Affiliation country: Canada